Thyroid Cancer

Thyroid cancer is a type of cancer that originates from the cells of the thyroid gland, a butterfly-shaped gland located at the base of the neck, just below the Adam’s apple. The thyroid gland plays a crucial role in regulating metabolism, growth, and development by producing thyroid hormones. While relatively uncommon compared to other cancers, its incidence has been increasing globally, making it a significant public health concern.

Biological Basis

The development of thyroid cancer, like other cancers, involves a complex interplay of genetic and environmental factors. At a fundamental level, it arises from uncontrolled cell growth due to mutations in the DNA of thyroid cells. These mutations can activate oncogenes (genes that promote cell growth) or inactivate tumor suppressor genes (genes that regulate cell growth and prevent cancer). Common genetic alterations include mutations in theBRAF gene, RAS genes, and rearrangements involving the RET/PTC and PAX8/PPARγ genes. Inherited genetic syndromes, such as Multiple Endocrine Neoplasia type 2 (MEN2), caused by germline mutations in the RETproto-oncogene, significantly increase the risk of specific types of thyroid cancer. Single Nucleotide Polymorphisms (SNPs) in various genes are also being investigated for their potential role in modulating an individual’s susceptibility to thyroid cancer.

Clinical Relevance

Thyroid cancer is typically diagnosed through physical examination, blood tests (to check thyroid hormone levels), ultrasound, and fine-needle aspiration biopsy of suspicious thyroid nodules. Most thyroid cancers are differentiated types (papillary and follicular), which tend to be slow-growing and have an excellent prognosis with appropriate treatment. Less common and more aggressive forms include medullary and anaplastic thyroid cancer. Treatment often involves surgery to remove the thyroid gland (thyroidectomy), followed by radioactive iodine therapy to destroy any remaining thyroid cancer cells. Hormone therapy with levothyroxine is also crucial to suppress thyroid-stimulating hormone (TSH) and prevent cancer recurrence. Regular follow-up and monitoring are essential for detecting recurrence and managing long-term health.

Social Importance

Despite its generally good prognosis, the rising incidence of thyroid cancer, particularly papillary thyroid cancer, raises concerns about its social and economic impact. It primarily affects individuals in their working and family-building years, with a higher prevalence in women. The diagnosis and treatment can lead to significant physical and psychological burden, including anxiety, depression, and changes in quality of life due to surgery, lifelong medication, and potential side effects of treatment. Furthermore, the economic costs associated with diagnosis, treatment, and long-term surveillance contribute to healthcare expenditures. Public awareness, early detection, and ongoing research into genetic predispositions and novel therapies are vital for improving patient outcomes and addressing the broader societal implications of thyroid cancer.

Limitations

Methodological and Statistical Considerations

Genetic association studies for complex diseases like thyroid cancer inherently face several methodological challenges. A primary limitation is the requirement for very large sample sizes to detect genetic variants that confer only a modest increase in risk, especially when considering the stringent statistical thresholds necessary for genome-wide significance (e.g., p < 5 × 10⁻⁸)^[1]. Initial findings from discovery cohorts often necessitate extensive replication in independent, equally large cohorts to validate associations and avoid reporting spurious signals or inflated effect sizes, a process that can be resource-intensive and time-consuming ^[2]. Without sufficient statistical power across both discovery and replication phases, the full spectrum of common genetic variants contributing to thyroid cancer risk may remain undiscovered, or reported findings may lack the robustness required for clinical application^[3].

Furthermore, the design and characteristics of study cohorts can introduce specific biases that impact the interpretability of results. Studies conducted in genetically isolated founder populations, while advantageous for certain types of genetic analyses, may not fully capture the genetic heterogeneity prevalent in broader, more diverse populations, potentially limiting the generalizability of identified associations ^[4]. Even within well-characterized cohorts, the specific genotyping strategies, such as those used for propagating genotypes through pedigrees to maximize cost-effectiveness, can influence the range and density of genetic variants that are effectively examined ^[5]. These inherent study design features and statistical constraints mean that findings must be interpreted within the context of the specific study population and methodology employed.

Population Diversity and Phenotypic Heterogeneity

The generalizability of genetic findings across different ancestral populations is a significant limitation in complex disease research, including thyroid cancer. Genetic variants can have different allele frequencies and potentially varying penetrance or effect sizes across distinct populations, meaning an association identified in one group may not hold true or be as strong in another^[6]. While international collaborations aim to address this by pooling data from diverse cohorts, ensuring that findings are uniformly applicable across all ancestries remains a challenge ^[7], ^[8], ^[9]. Assumptions of common relative risks across populations, despite differing allele frequencies, may oversimplify the complex interplay of genetic and environmental factors unique to each group ^[6].

Another critical limitation pertains to the precise definition and consistent measurement of the thyroid cancer phenotype itself. Studies often rely on self-reported disease status, such as a diagnosis of “thyroid cancer” or a history of “thyrectomy,” which can introduce variability and potential misclassification compared to more rigorously confirmed clinical diagnoses^[5]. While advanced imaging techniques like ultrasound and color-Doppler sonography provide objective measures for nodule characteristics, the detailed pathological features, clinical course, or specific subtypes of thyroid cancer may not always be uniformly captured across all research cohorts^[5]. This phenotypic heterogeneity can obscure or dilute true genetic associations, particularly for variants that might be specific to certain clinical presentations or prognoses of thyroid cancer.

Incomplete Etiological Understanding

Current genetic research on thyroid cancer, largely through genome-wide association studies, has focused on identifying common genetic variants, yet this approach provides only a partial understanding of the disease’s complex etiology. Thyroid cancer, as a complex trait, is influenced by a multitude of genetic factors, including potentially rare variants or structural changes not typically covered by common SNP arrays, as well as significant non-genetic contributions^[10], ^[4]. The identified genetic loci often explain only a fraction of the estimated heritability, indicating that a substantial portion of the genetic risk, often referred to as “missing heritability,” remains to be discovered. This suggests that the current genetic models are incomplete and that further research into diverse genetic architectures is necessary.

Despite advancements in pinpointing specific susceptibility loci, significant knowledge gaps persist regarding the full spectrum of factors contributing to thyroid cancer development and progression. The ongoing need for “additional risk variants” through expanded meta-analyses and novel research approaches underscores that many genetic determinants, and their intricate interactions, have yet to be elucidated^[2]. Furthermore, the critical interplay between genetic predispositions and environmental exposures, which is paramount for the development of most complex diseases, is frequently not comprehensively assessed or integrated within the scope of genetic association studies. This leaves a broader understanding of gene-environment interactions largely unexplored, representing a substantial area for future research.

Variants

Genetic variants play a crucial role in influencing an individual’s susceptibility to thyroid cancer, the most common endocrine malignancy, whose incidence has been rising in industrialized countries over recent decades^[11]. The risk of thyroid cancer is known to have a significant genetic component, extending beyond immediate family members^[11]. Understanding specific genetic variations and their associated genes provides insight into the complex mechanisms underlying disease development. Thyroid cancer is histologically categorized into four main groups: papillary (PTC), follicular (FTC), medullary (MTC), and undifferentiated (anaplastic) thyroid carcinomas^[11].

Several long non-coding RNAs (lncRNAs) and their associated variants are implicated in thyroid cancer risk and progression. Variants likers16857609 and rs57481445 in the DIRC3(Divergent transcript in renal carcinoma 3) gene, along withrs13290258 and rs925489 in PTCSC2 (Papillary Thyroid Carcinoma Susceptibility Candidate 2), are of particular interest. LncRNAs such as DIRC3, PTCSC2, LINC00609 (including rs8020481 ), LINC01117 (rs369713868 ), and MSRB3-AS1 (rs9971770 ) function as critical regulators of gene expression, influencing processes like cell proliferation, apoptosis, and metastasis. Polymorphisms within these lncRNA genes can alter their expression levels or functional interactions, thereby modulating the risk of thyroid cancer by affecting key cellular pathways^[11]. For instance, PTCSC2 has been specifically associated with susceptibility to papillary thyroid carcinoma, suggesting its direct involvement in thyroid cell growth and differentiation.

The TERT (Telomerase Reverse Transcriptase) gene, with variants such as rs7734992 , is a well-known oncogene frequently implicated in various cancers, including thyroid cancer. TERT encodes the catalytic subunit of telomerase, an enzyme vital for maintaining telomere length and cellular immortality. While telomerase activity is typically low in most adult cells, its reactivation in cancerous cells, often driven by variants in the TERT promoter region, promotes uncontrolled cell division and tumor growth. Such variants can significantly increase TERT expression, contributing to a higher risk of more aggressive forms of thyroid cancer^[11]. Similarly, NRG1 (Neuregulin 1), through variants like rs3802160 and rs9642727 , plays a role in cell-cell communication, growth, and survival via ERBB receptor signaling. Dysregulation of NRG1 pathways, possibly due to these variants, can lead to altered cell proliferation and migration, processes fundamental to tumorigenesis in the thyroid gland.

Other genes and gene regions, such as EPB41L4A (Erythrocyte Membrane Protein Band 4.1 Like 4A) with variant rs73227498 , and ZNF765 (Zinc Finger Protein 765) with rs537876632 , also contribute to thyroid cancer susceptibility. EPB41L4A encodes a cytoskeletal protein involved in cell adhesion and migration, often acting as a tumor suppressor by regulating cell polarity; variants may disrupt this function, promoting cancer progression. ZNF765, a zinc finger transcription factor, regulates gene expression, and variants could alter its binding to DNA or interaction with other proteins, thereby affecting genes critical for thyroid cell growth and differentiation. Furthermore, the region encompassingLINC00609 - MBIP (MAPK-activating death domain-containing protein-interacting protein) and its variant rs116909374 highlights the interplay between lncRNAs and protein-coding genes. MBIP is involved in apoptosis and MAPK signaling, and variants in this combined region might affect the expression or function of LINC00609 or MBIP, influencing cell survival pathways relevant to thyroid cancer development^[11].

Key Variants

RS ID	Gene	Related Traits
rs16857609 rs57481445	DIRC3	breast carcinoma estrogen-receptor negative breast cancer thyroid carcinoma thyroid cancer
rs13290258 rs925489	PTCSC2	body height hypothyroidism thyroid cancer glucose measurement
rs3802160 rs9642727	NRG1	thyroid cancer
rs116909374	LINC00609 - MBIP	thyroid carcinoma thyroid stimulating hormone amount level of thyrotropin subunit beta in blood hypothyroidism differentiated thyroid carcinoma
rs8020481	LINC00609	thyroid cancer
rs73227498	EPB41L4A	thyroid carcinoma thyroid cancer
rs7734992	TERT	renal carcinoma clear cell renal carcinoma neutrophil percentage of leukocytes spleen volume level of tumor necrosis factor ligand superfamily member 6 in blood
rs9971770	MSRB3-AS1	thyroid stimulating hormone amount Toxic Nodular Goiter thyroid cancer multinodular goiter nontoxic goiter
rs369713868	LINC01117	thyroid cancer
rs537876632	ZNF765	thyroid cancer

Definition and Core Histological Classification

Thyroid cancer is a malignant neoplasm originating from the cells of the thyroid gland, which is primarily classified based on its histological characteristics. The predominant classification system categorizes thyroid cancer into four main groups: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), medullary thyroid carcinoma (MTC), and undifferentiated or anaplastic thyroid carcinomas (ATC)^[11]. These histological distinctions are crucial for prognosis and treatment planning, as they represent distinct biological behaviors and clinical courses. Papillary and follicular thyroid carcinomas are the most common forms, accounting for approximately 80–85% and 10–15% of all thyroid tumors, respectively ^[11]. In contrast, medullary thyroid cancer constitutes about 1–3% of cases, while anaplastic thyroid cancer, though rare at 1% to 5% of all thyroid carcinomas, is notably one of the most aggressive human malignancies^[11].

Subtype Characteristics and Genetic Predisposition

Each thyroid cancer subtype possesses unique traits, pathogenesis, and associated risk factors. Papillary thyroid carcinoma, the most prevalent form, is associated with risk factors such as ionizing radiation exposure, nodular thyroid disease, and a family history of thyroid cancer^[11]. Follicular thyroid carcinoma, the second most common, has an established risk factor in iodine intake deficiency ^[11]. Medullary thyroid cancer is distinct in its origin from parafollicular C-cells and is frequently linked to mutations in the RET oncogene, explaining its pathogenesis and its association with the multiple endocrine neoplasia type 2 (MEN2) syndrome^[11]. Beyond these specific genetic links, broader genetic susceptibility to thyroid cancer has been identified, with common variants on chromosomes 9q22.33 and 14q13.3 shown to predispose individuals in European populations to the disease^[11].

Diagnostic Criteria and Measurement Modalities

The diagnosis and characterization of thyroid cancer and related conditions rely on a combination of clinical criteria, imaging, and biochemical markers. Thyroid ultrasound examination is a fundamental measurement approach, utilizing a linear transducer to perform transverse and longitudinal scans to assess overall thyroid size, echotexture, and the presence, structure, size, and vascularization of nodules^[5]. Thyroid volume is precisely calculated using the ellipsoid formula (length × breadth × width × 0.523), with goiter defined when the total thyroid volume exceeds the mean normal range ^[5]. Additionally, diffuse alteration of echotexture indicative of chronic thyropathies can be detected. Biochemical assessment often includes measuring serum thyroid-stimulating hormone (TSH) levels, typically performed with highly sensitive third-generation assays, such as chemoluminescence assays, which have a lower limit of detection of 0.01 mU/L and a wide detection range^[5]. Self-reported thyroid disease status, encompassing conditions like autoimmune thyroiditis, prior thyroid cancer, or partial/total thyrectomy, also contributes to the diagnostic and patient history profile^[5].

Histological Classification and Disease Phenotypes

Thyroid cancer is characterized by distinct histological classifications, which define different clinical phenotypes and severity ranges. The primary forms include papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), medullary thyroid carcinoma (MTC), and undifferentiated or anaplastic thyroid carcinoma^[11]. PTC constitutes the majority of cases, accounting for 80-85% of all thyroid tumors, followed by FTC at 10-15% ^[11]. Medullary thyroid cancer, comprising 1-3% of cases, is notably associated with the multiple endocrine neoplasia type 2 (MEN2) syndrome, with its pathogenesis often linked to mutations in the RET oncogene^[11]. Anaplastic thyroid carcinoma, while accounting for a smaller proportion (1-5%), is recognized as one of the most aggressive human malignancies, although its pathogenesis is less understood ^[11].

Epidemiological Incidence and Demographic Variability

Thyroid cancer exhibits specific epidemiological patterns and demographic variability, which are important for understanding its overall presentation. Incidence rates demonstrate inter-individual and sex-based differences; for instance, data from Iceland indicate an annual incidence of 4.6 per 100,000 for males compared to 12.1 per 100,000 for females^[11]. These objective measures of incidence highlight variations in disease burden across different demographic groups. Such patterns suggest potential underlying biological or environmental factors that influence disease manifestation and prevalence, contributing to the overall heterogeneity observed in thyroid cancer presentation.

Predisposing Factors and Genetic Correlations

Beyond demographic patterns, specific predisposing factors and genetic correlations are recognized in thyroid cancer, offering insights into its etiology and potential diagnostic flags. Established risk factors vary by histological subtype, with follicular thyroid carcinoma linked to iodine deficiency, while papillary thyroid carcinoma is associated with exposure to ionizing radiation, the presence of nodular thyroid disease, and a family history of the condition^[11]. Furthermore, genetic studies have identified common sequence variants, such as those on 9q22.33 and 14q13.3, which predispose individuals in European populations to thyroid cancer^[11]. These genetic biomarkers and environmental influences contribute to understanding the variable presentation and risk stratification of the disease.

The biological background of thyroid cancer, like other cancers, involves complex molecular, cellular, and genetic mechanisms that disrupt normal physiological processes. Understanding these intricate biological underpinnings is crucial for deciphering its etiology, progression, and potential therapeutic targets.

Genetic Basis of Cancer Susceptibility

The development of cancer is often influenced by an individual’s genetic makeup, where specific inherited sequence variants can significantly modulate disease risk. Extensive research, particularly through genome-wide association studies (GWAS), has been instrumental in identifying numerous susceptibility loci across the human genome for various cancer types^[9]. These studies pinpoint specific chromosomal regions that harbor genetic variations impacting cancer risk, providing insights into the genetic mechanisms underlying disease predisposition. For instance, studies have identified a locus at 22q13 associated with prostate cancer risk^[12], and novel breast cancer susceptibility loci on 3p24 and 17q23.2^[8], highlighting the role of common genetic variants in altering gene functions and regulatory elements.

Molecular and Cellular Disruptions in Oncogenesis

Genetic alterations, such as the sequence variants identified through GWAS, can lead to profound disruptions in critical molecular and cellular pathways. These disruptions often involve aberrant signaling pathways, altered metabolic processes, and compromised cellular functions that collectively drive oncogenesis. For example, susceptibility loci identified for pancreatic cancer on chromosomes 13q22.1, 1q32.1, and 5p15.33^[13], or for lung cancer at 5p15.33^[7], suggest that genes within these regions may regulate fundamental cellular activities. Such genetic changes can impact the expression patterns of genes, leading to an imbalance in cell growth, differentiation, and survival that characterizes cancer.

Regulatory Networks and Key Biomolecules

The intricate regulatory networks governing cell behavior are often compromised in cancer due to alterations in key biomolecules. Genetic variants can affect the structure or function of critical proteins, enzymes, receptors, hormones, and transcription factors, thereby perturbing normal cellular communication and control. For instance, variants in regions like CDKN2B and RTEL1, which are associated with high-grade glioma susceptibility^[14], likely influence gene regulation and DNA repair mechanisms through their encoded proteins. These disruptions can lead to dysregulated cellular functions, allowing cells to bypass normal growth constraints and evade programmed cell death.

Pathophysiological Manifestations and Tissue-Level Impacts

The molecular and cellular disruptions in cancer culminate in observable pathophysiological processes that affect tissue and organ-level biology. These processes include the initiation of disease mechanisms, abnormal developmental processes, and severe disruptions to homeostatic balance within the affected organ. The familial aggregation of common sequence variants in lung cancer^[15] illustrates how genetic predispositions can manifest as organ-specific effects. Over time, these localized changes can lead to tissue interactions that promote tumor growth and metastasis, ultimately resulting in systemic consequences that affect the entire organism.

Clinical Relevance

Genetic Susceptibility and Risk Stratification

Research has identified common genetic variants that predispose individuals to thyroid cancer, particularly within European populations. Specifically, variants located on chromosomes 9q22.33 and 14q13.3 have been associated with an increased susceptibility to developing this malignancy^[11]. These findings highlight the genetic component in thyroid cancer etiology, suggesting that inherited factors play a role in an individual’s risk profile and can be utilized for enhanced risk assessment.

The identification of such susceptibility loci holds significant clinical relevance for risk stratification, enabling the potential identification of individuals at higher genetic risk for thyroid cancer^[11]. This genetic insight could contribute to personalized medicine approaches, where risk profiles might inform tailored screening strategies or enhanced surveillance for those carrying these variants. While further research is typically needed to translate these findings into routine clinical practice, understanding these genetic predispositions is a foundational step toward more targeted prevention and early detection efforts for improved patient care.

Frequently Asked Questions About Thyroid Cancer

These questions address the most important and specific aspects of thyroid cancer based on current genetic research.

---

1. My mom had thyroid cancer; will I get it too?

It depends on the type of thyroid cancer your mom had. Some forms, like medullary thyroid cancer, are strongly linked to inherited genetic changes, specifically germline mutations in theRET proto-oncogene, which cause syndromes like MEN2. If your family has one of these inherited syndromes, your risk would be significantly higher. For most common types, while genetics play a role, it’s usually a combination of factors.

2. I’m a woman in my 30s; am I at higher risk?

Yes, statistically, you are. Thyroid cancer is more prevalent in women and often affects individuals during their working and family-building years. While the exact reasons for this gender disparity aren’t fully understood, it’s a consistent pattern observed globally.

3. Can my lifestyle choices prevent thyroid cancer?

Thyroid cancer develops from a complex interplay of genetic and environmental factors. While a healthy lifestyle generally supports overall well-being, specific lifestyle changes aren’t detailed in preventing the genetic mutations that cause it. Inherited genetic syndromes and specific gene mutations likeBRAF or RASplay a significant role, which lifestyle alone cannot entirely counteract.

4. Do my genes affect how serious my thyroid cancer might be?

Yes, your genetic makeup can influence the aggressiveness of thyroid cancer. For example, mutations in theBRAFgene are often associated with more aggressive forms of papillary thyroid cancer. Inherited mutations in theRETproto-oncogene can lead to medullary thyroid cancer, which is less common but can be more aggressive than differentiated types.

5. If I beat thyroid cancer, could it come back?

It’s possible for thyroid cancer to recur, which is why regular follow-up and monitoring are essential. Treatment often includes hormone therapy with levothyroxine to suppress TSH, which helps prevent recurrence. While genetic factors contributing to recurrence aren’t explicitly detailed, ongoing surveillance helps detect any remaining or new cancer cells.

6. Should I get checked for thyroid cancer regularly?

Given the rising incidence of thyroid cancer, especially papillary thyroid cancer, public awareness and early detection are vital. If you have risk factors like a family history or suspicious thyroid nodules, regular check-ups, including physical exams and potentially ultrasound, are important for early diagnosis and better outcomes.

7. Does my family’s ethnic background change my risk?

Yes, it can. Genetic variants can have different frequencies and effects across distinct ancestral populations. This means that an association or risk identified in one ethnic group might not be the same in another. Research aims to understand these differences to ensure findings are applicable across diverse populations.

8. Can a DNA test tell me my personal risk?

For some specific types of thyroid cancer, like medullary thyroid cancer, a DNA test can identify germline mutations in theRETproto-oncogene that significantly increase your risk. For more common types, while single nucleotide polymorphisms (SNPs) are being investigated for susceptibility, current genetic models are still incomplete, and they only explain a fraction of the overall risk.

9. Why are more people getting thyroid cancer these days?

The incidence of thyroid cancer has been increasing globally, making it a significant public health concern. While the article doesn’t pinpoint a single reason, improved diagnostic techniques, such as more frequent and advanced imaging, may contribute to detecting smaller cancers that might have gone unnoticed before.

10. Why do some people’s thyroid cancer spread faster?

The aggressiveness and spread of thyroid cancer can vary significantly. Less common types like medullary and anaplastic thyroid cancer are inherently more aggressive than the more common papillary and follicular types. This difference in behavior is often linked to specific genetic alterations, such asBRAF mutations or RET/PTC rearrangements, which can drive more rapid and uncontrolled cell growth.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Murabito JM et al. “A genome-wide association study of breast and prostate cancer in the NHLBI’s Framingham Heart Study.”BMC Med Genet. 2007. PMID: 17903305.

[2] Wang Y et al. “Common 5p15.33 and 6p21.33 variants influence lung cancer risk.”Nat Genet. 2008. PMID: 18978787.

[3] Houlston RS et al. “Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer.”Nat Genet. 2009. PMID: 19011631.

[4] Lowe JK et al. “Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae.” PLoS Genet. 2009. PMID: 19197348.

[5] Arnaud-Lopez L et al. “Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function.”Am J Hum Genet. 2008. PMID: 18514160.

[6] Kiemeney LA et al. “Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.”Nat Genet. 2008. PMID: 18794855.

[7] McKay JD et al. “Lung cancer susceptibility locus at 5p15.33.”Nat Genet. 2008. PMID: 18978790.

[8] Ahmed S et al. “Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.”Nat Genet. 2009. PMID: 19330027.

[9] Easton DF et al. “Genome-wide association study identifies novel breast cancer susceptibility loci.”Nature. 2007. PMID: 17529967.

[10] Broderick P et al. “Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study.”Cancer Res. 2009. PMID: 19654303.

[11] Gudmundsson J, Sulem P, Gudbjartsson D, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations.Nat Genet. 2009;41(4):460-464.

[12] Sun J et al. “Sequence variants at 22q13 are associated with prostate cancer risk.” Cancer Res. 2009. PMID: 19117981.

[13] Petersen GM et al. “A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.” Nat Genet. 2010. PMID: 20101243.

[14] Wrensch M et al. “Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.” Nat Genet. 2009. PMID: 19578366.

[15] Liu P et al. “Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer.” J Natl Cancer Inst. 2008. PMID: 18780872.